This clinical trial is focused on studying Multiple Sclerosis, specifically the type known as Relapsing-Remitting Multiple Sclerosis. The study will compare two different treatment approaches. One approach involves continuing with a type of medication called anti-CD20 therapy, which includes drugs like Ocrelizumab and Rituximab. The other approach involves switching from anti-CD20 therapy to other treatments known as platform therapies, which include medications such as Ofatumumab, Dimethyl Fumarate, Diroximel Fumarate, Teriflunomide, Glatiramer Acetate, Peginterferon Beta-1a, and Interferon Beta-1a.

The purpose of the study is to see if switching to platform therapies is not worse than continuing with anti-CD20 therapy in terms of keeping the disease under control. Participants will be randomly assigned to one of the two treatment groups. The study will last for about three years, during which time participants will receive their assigned treatment and have regular check-ups. These check-ups will include clinical evaluations and MRI scans to monitor disease activity, which means looking for any new symptoms or changes in the brain that might indicate the disease is getting worse.

Throughout the study, researchers will also keep track of any relapses, changes in disability, and any side effects or infections that might occur. They will also measure certain substances in the blood, like B-cells and immunoglobulins, which are part of the immune system. Additionally, the study will look at brain volume and levels of a protein called neurofilament light chain, which can indicate nerve damage. The overall goal is to understand which treatment approach is better for managing the disease while considering the impact on quality of life and healthcare costs.